DFDA

Liver Transplantation

Treatment for Hepatoblastoma

Effectiveness
80%
Safety Score
25%
Clinical Trials
5
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Time to Effect
immediate (tumor removal), long recovery
Treatment Duration
Acute event, lifelong immunosuppression
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$30,000
Side Effect Mgmt:$20,000
Total Annual:$580,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$110,000/QALY
QALYs Gained
20
Outcome-Based Costs
Cost per Responder
$725,000
Cost per Remission
$773,333.33
Liver Transplantation Outcomes

for Hepatoblastoma

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Remission Rate
+75%
Common Side Effects
Organ rejection
+20%
Infection
+50%
Biliary complications
+15%
Kidney dysfunction
+30%
Post-transplant lymphoproliferative disorder (PTLD)
+5%

Sources:

oaepublish.com
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Liver Transplantation in Hepatoblastoma

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

NCT00980460ACTIVE NOT RECRUITINGPHASE3
View Study
236 participants
INTERVENTIONAL
Birmingham, United States +208 more
Started: Sep 14, 2009
Completed Clinical Trials
1 completed trial for Liver Transplantation in Hepatoblastoma

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

NCT00007813COMPLETEDPHASE1
View Study
21 participants
INTERVENTIONAL
Baltimore, United States
Started: May 31, 1997